Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

CHITOSAN COATED ROSUVASTATIN NANOSTRUCTURED LIPID CARRIERS: FORMULATION, IN VITRO CHARACTERIZATION AND STORAGE ASSESSMENTS

View through CrossRef
Background and Objective: Rosuvastatin calcium (ROS-Ca) is a synthetic, highly potent third-generation HMG-CoA reductase inhibitor with significant hypocholesterolemic effects. The objective of this study was to develop and characterize nanostructured lipid carriers (NLCs) as a delivery system for the poorly water-soluble drug rosuvastatin calcium (ROS-Ca), with the aim of enhancing its dissolution rate and improving oral bioavailability. Methods: ROS-NLCs is prepared by hot homogenization–ultrasonication technique then the prepared formulations were further characterized. Finally compare their characteristics to the corresponding a positively charged chitosan coated to develop new CH-ROS-NLCs. In this study, glyceryl monostearate (GMS) was selected as solid lipids and Transcutol® HP as a liquid lipid, to develop ROS-NLC (nanostructured lipid carrier). Results: The physicochemical properties were achieved. The prepared ROS-NLC formulation was showed in nanometric size (121.6±6.2 nm) with encapsulation efficiency (63±0.2%). Furthermore, ROS-NLC and CH-ROS-NLC appeared almost spherical nanoparticles in morphology under transmission electron microscope (TEM). DSC, XRD and FT-IR analysis showed that ROS was miscible, compatible, and incorporated into NLCs in amorphous form not in native crystalline state. Conclusion: The previously results showed that ROS-Ca was successfully encapsulated into nanostructured lipid carriers (NLCs) which coated with chitosan CH-ROS-NLC to overcome the above-mentioned defects and, it was ensured that nanostructured lipid carriers have high beneficial effect for enhancing and improving the oral bioavailability of poorly water-soluble drugs such as Rosuvastatin.                     Peer Review History: Received 9 April 2025;   Reviewed 12 May 2025; Accepted 22 June; Available online 15 July 2025 Academic Editor: Dr. DANIYAN Oluwatoyin Michael, Obafemi Awolowo University, ILE-IFE, Nigeria, toyinpharm@gmail.com Reviewers: Dr. Areen Alshweiat, University of Szeged, Hungary, areen.alshweiat@hu.edu.jo Dr. Awofisayo, O Abosede, University of Uyo, Nigeria, shalomgirl08@yahoo.com
Title: CHITOSAN COATED ROSUVASTATIN NANOSTRUCTURED LIPID CARRIERS: FORMULATION, IN VITRO CHARACTERIZATION AND STORAGE ASSESSMENTS
Description:
Background and Objective: Rosuvastatin calcium (ROS-Ca) is a synthetic, highly potent third-generation HMG-CoA reductase inhibitor with significant hypocholesterolemic effects.
The objective of this study was to develop and characterize nanostructured lipid carriers (NLCs) as a delivery system for the poorly water-soluble drug rosuvastatin calcium (ROS-Ca), with the aim of enhancing its dissolution rate and improving oral bioavailability.
Methods: ROS-NLCs is prepared by hot homogenization–ultrasonication technique then the prepared formulations were further characterized.
Finally compare their characteristics to the corresponding a positively charged chitosan coated to develop new CH-ROS-NLCs.
In this study, glyceryl monostearate (GMS) was selected as solid lipids and Transcutol® HP as a liquid lipid, to develop ROS-NLC (nanostructured lipid carrier).
Results: The physicochemical properties were achieved.
The prepared ROS-NLC formulation was showed in nanometric size (121.
6±6.
2 nm) with encapsulation efficiency (63±0.
2%).
Furthermore, ROS-NLC and CH-ROS-NLC appeared almost spherical nanoparticles in morphology under transmission electron microscope (TEM).
DSC, XRD and FT-IR analysis showed that ROS was miscible, compatible, and incorporated into NLCs in amorphous form not in native crystalline state.
Conclusion: The previously results showed that ROS-Ca was successfully encapsulated into nanostructured lipid carriers (NLCs) which coated with chitosan CH-ROS-NLC to overcome the above-mentioned defects and, it was ensured that nanostructured lipid carriers have high beneficial effect for enhancing and improving the oral bioavailability of poorly water-soluble drugs such as Rosuvastatin.
                    Peer Review History: Received 9 April 2025;   Reviewed 12 May 2025; Accepted 22 June; Available online 15 July 2025 Academic Editor: Dr.
DANIYAN Oluwatoyin Michael, Obafemi Awolowo University, ILE-IFE, Nigeria, toyinpharm@gmail.
com Reviewers: Dr.
Areen Alshweiat, University of Szeged, Hungary, areen.
alshweiat@hu.
edu.
jo Dr.
Awofisayo, O Abosede, University of Uyo, Nigeria, shalomgirl08@yahoo.
com.

Related Results

Synthesis and Investigation into Apatite-forming Ability of Hydroxyapatite/Chitosan-based Scaffold
Synthesis and Investigation into Apatite-forming Ability of Hydroxyapatite/Chitosan-based Scaffold
In this study, porous scaffolds were fabricated using inorganic material-hydroxyapatite and chitosan for bone-tissue engineering. The combination of hydroxyapatite and chitosan may...
Nanostructured lipid carriers loaded with cannabidiol: A novel antibiofilm approach
Nanostructured lipid carriers loaded with cannabidiol: A novel antibiofilm approach
Introduction: Staphylococcus aureus and Staphylococcus epidermidis are major contributors to skin dysbiosis and infections, e.g. folliculitis and intravascular catheter infections,...
Rosuvastatin Alone or With Extended‐Release Niacin: A New Therapeutic Option for Patients With Combined Hyperlipidemia
Rosuvastatin Alone or With Extended‐Release Niacin: A New Therapeutic Option for Patients With Combined Hyperlipidemia
Combination therapy with a statin and niacin may provide optimal therapy for patients with combined hyperlipidemia and low levels of highdensity lipoprotein (HDL) cholesterol. The ...
Comparison Between Atorvastatin and Rosuvastatin on Anti- Thrombogenic Effect in Patients with Hyperlipidemia
Comparison Between Atorvastatin and Rosuvastatin on Anti- Thrombogenic Effect in Patients with Hyperlipidemia
Background: Atorvastatin and rosuvastatin are two widely used HMG-CoA reductase inhibitors (statins). These are used as lipid-lowering drugs to reduce atherosclerosis-induced cardi...
Development of Solid Self – Nanoemulsified Drug Delivery System Containing Rosuvastatin
Development of Solid Self – Nanoemulsified Drug Delivery System Containing Rosuvastatin
This study aims to solidify the self-nanoemulsifying drug delivery system with rosuvastatin (SNEDDS Ros) for application in solid dosage forms. The liquid SNEDDS Ros system is soli...
BIODEGRADATION OF CHITOSAN MEMBRANE SCALES OF HARUAN FISH (Channa striata)-HYDROXYAPATITE IN ARTIFICIAL SALIVA SOLUTION
BIODEGRADATION OF CHITOSAN MEMBRANE SCALES OF HARUAN FISH (Channa striata)-HYDROXYAPATITE IN ARTIFICIAL SALIVA SOLUTION
Background: Membrane materials for surgical procedures using Guided Tissue Regeneration (GTR) are Polytetrafluoroethylene (PTFE) and collagen, but have the disadvantage of requirin...
GW24-e0760 Effects of rosuvastatin on rats with dyslipidemia and antiatherosclerotic
GW24-e0760 Effects of rosuvastatin on rats with dyslipidemia and antiatherosclerotic
Objectives To explore the regulating lipid effects of Rosuvastatin on rats with dyslipidemia and its antiatherosclerotic effects. ...

Back to Top